331 related articles for article (PubMed ID: 25203718)
1. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.
Meissner EG; Lee YJ; Osinusi A; Sims Z; Qin J; Sturdevant D; McHutchison J; Subramanian M; Sampson M; Naggie S; Patel K; Remaley AT; Masur H; Kottilil S
Hepatology; 2015 Mar; 61(3):790-801. PubMed ID: 25203718
[TBL] [Abstract][Full Text] [Related]
2. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome.
Meissner EG; Wu D; Osinusi A; Bon D; Virtaneva K; Sturdevant D; Porcella S; Wang H; Herrmann E; McHutchison J; Suffredini AF; Polis M; Hewitt S; Prokunina-Olsson L; Masur H; Fauci AS; Kottilil S
J Clin Invest; 2014 Aug; 124(8):3352-63. PubMed ID: 24983321
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
Younossi ZM; Stepanova M; Estep M; Negro F; Clark PJ; Hunt S; Song Q; Paulson M; Stamm LM; Brainard DM; Subramanian GM; McHutchison JG; Patel K
J Hepatol; 2016 Jan; 64(1):29-36. PubMed ID: 26341824
[TBL] [Abstract][Full Text] [Related]
4. Improvement of glucose and lipid metabolism with pegylated interferon-a plus ribavirin therapy in Chinese patients chronically infected with genotype 1b hepatitis C virus.
Qing S; Ji D; Li B; Li F; Wang Y; Niu X; Ling B; Meng Y; Lau G; Chen G
Ann Saudi Med; 2015; 35(4):293-7. PubMed ID: 26497709
[TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
Rodriguez-Torres M; Lawitz E; Kowdley KV; Nelson DR; Dejesus E; McHutchison JG; Cornpropst MT; Mader M; Albanis E; Jiang D; Hebner CM; Symonds WT; Berrey MM; Lalezari J
J Hepatol; 2013 Apr; 58(4):663-8. PubMed ID: 23183528
[TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.
Lawitz E; Poordad F; Brainard DM; Hyland RH; An D; Dvory-Sobol H; Symonds WT; McHutchison JG; Membreno FE
Hepatology; 2015 Mar; 61(3):769-75. PubMed ID: 25322962
[TBL] [Abstract][Full Text] [Related]
7. The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: temporary? permanent?
Özdoğan O; Yaraş S; Ateş F; Üçbilek E; Sezgin O; Altıntaş E
Turk J Gastroenterol; 2020 May; 31(5):384-392. PubMed ID: 32519958
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
Kowdley KV; Lawitz E; Crespo I; Hassanein T; Davis MN; DeMicco M; Bernstein DE; Afdhal N; Vierling JM; Gordon SC; Anderson JK; Hyland RH; Dvory-Sobol H; An D; Hindes RG; Albanis E; Symonds WT; Berrey MM; Nelson DR; Jacobson IM
Lancet; 2013 Jun; 381(9883):2100-7. PubMed ID: 23499440
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
Sirinawasatien A; Techasirioangkun T
PLoS One; 2020; 15(2):e0229517. PubMed ID: 32106270
[TBL] [Abstract][Full Text] [Related]
10. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
Townsend K; Meissner EG; Sidharthan S; Sampson M; Remaley AT; Tang L; Kohli A; Osinusi A; Masur H; Kottilil S
AIDS Res Hum Retroviruses; 2016 May; 32(5):456-62. PubMed ID: 26559180
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
Lawitz E; Lalezari JP; Hassanein T; Kowdley KV; Poordad FF; Sheikh AM; Afdhal NH; Bernstein DE; Dejesus E; Freilich B; Nelson DR; Dieterich DT; Jacobson IM; Jensen D; Abrams GA; Darling JM; Rodriguez-Torres M; Reddy KR; Sulkowski MS; Bzowej NH; Hyland RH; Mo H; Lin M; Mader M; Hindes R; Albanis E; Symonds WT; Berrey MM; Muir A
Lancet Infect Dis; 2013 May; 13(5):401-8. PubMed ID: 23499158
[TBL] [Abstract][Full Text] [Related]
13. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.
Meissner EG; Bon D; Prokunina-Olsson L; Tang W; Masur H; O'Brien TR; Herrmann E; Kottilil S; Osinusi A
J Infect Dis; 2014 Jun; 209(11):1700-4. PubMed ID: 24367041
[TBL] [Abstract][Full Text] [Related]
14. Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
Smith MA; Chan J; Mohammad RA
Ann Pharmacother; 2015 Mar; 49(3):343-50. PubMed ID: 25515863
[TBL] [Abstract][Full Text] [Related]
15. Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin.
Rower JE; Meissner EG; Jimmerson LC; Osinusi A; Sims Z; Petersen T; Bushman LR; Wolfe P; McHutchison JG; Kottilil S; Kiser JJ
J Antimicrob Chemother; 2015 Aug; 70(8):2322-9. PubMed ID: 25971261
[TBL] [Abstract][Full Text] [Related]
16. Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study.
Butt AA; Umbleja T; Andersen JW; Sherman KE; Chung RT;
Clin Infect Dis; 2012 Sep; 55(5):631-8. PubMed ID: 22563020
[TBL] [Abstract][Full Text] [Related]
17. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
Kan H; Imamura M; Kawakami Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Kobayashi T; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Aikata H; Hayes CN; Miki D; Ochi H; Honda Y; Mori N; Takaki S; Tsuji K; Chayama K
J Med Virol; 2017 Nov; 89(11):1963-1972. PubMed ID: 28657143
[TBL] [Abstract][Full Text] [Related]
18. Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.
Ohya K; Akuta N; Suzuki F; Fujiyama S; Kawamura Y; Kominami Y; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2018 May; 90(5):919-925. PubMed ID: 29315652
[TBL] [Abstract][Full Text] [Related]
19. Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection.
Asahina Y; Itoh Y; Ueno Y; Matsuzaki Y; Takikawa Y; Yatsuhashi H; Genda T; Ikeda F; Matsuda T; Dvory-Sobol H; Jiang D; Massetto B; Osinusi AO; Brainard DM; McHutchison JG; Kawada N; Enomoto N
Liver Int; 2018 Sep; 38(9):1552-1561. PubMed ID: 29297980
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
